IL312382A - COMPOUNDS AND METHODS OF ORAL ADMINISTRATION - Google Patents

COMPOUNDS AND METHODS OF ORAL ADMINISTRATION

Info

Publication number
IL312382A
IL312382A IL312382A IL31238224A IL312382A IL 312382 A IL312382 A IL 312382A IL 312382 A IL312382 A IL 312382A IL 31238224 A IL31238224 A IL 31238224A IL 312382 A IL312382 A IL 312382A
Authority
IL
Israel
Prior art keywords
polypeptide
seq
construct
polypeptide construct
amino acid
Prior art date
Application number
IL312382A
Other languages
English (en)
Hebrew (he)
Inventor
Thai Ngoc
Pollett Jonathan
Original Assignee
Imagine Pharma Llc
Thai Ngoc
Pollett Jonathan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imagine Pharma Llc, Thai Ngoc, Pollett Jonathan filed Critical Imagine Pharma Llc
Publication of IL312382A publication Critical patent/IL312382A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/505Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
IL312382A 2021-12-11 2022-12-09 COMPOUNDS AND METHODS OF ORAL ADMINISTRATION IL312382A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163288579P 2021-12-11 2021-12-11
PCT/US2022/081277 WO2023108126A1 (en) 2021-12-11 2022-12-09 Compositions and methods for oral administration

Publications (1)

Publication Number Publication Date
IL312382A true IL312382A (en) 2024-06-01

Family

ID=86731317

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312382A IL312382A (en) 2021-12-11 2022-12-09 COMPOUNDS AND METHODS OF ORAL ADMINISTRATION

Country Status (11)

Country Link
US (1) US20250388638A1 (https=)
EP (1) EP4444352A4 (https=)
JP (1) JP2024545981A (https=)
KR (1) KR20240141165A (https=)
CN (1) CN118613284A (https=)
AU (1) AU2022405604A1 (https=)
CA (1) CA3235948A1 (https=)
IL (1) IL312382A (https=)
MX (1) MX2024007105A (https=)
WO (1) WO2023108126A1 (https=)
ZA (1) ZA202404443B (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US20070042392A1 (en) * 2000-02-03 2007-02-22 Nuvelo, Inc. Novel nucleic acids and polypeptides
KR100944034B1 (ko) * 2007-04-19 2010-02-24 한올제약주식회사 프로테아제-내성 폴리펩티드의 경구 투여 제형
KR102497242B1 (ko) * 2016-11-13 2023-02-09 이매진 파마 당뇨병, 고혈압 및 고콜레스테롤혈증을 치료하기 위한 조성물 및 방법
PL3746111T3 (pl) * 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową

Also Published As

Publication number Publication date
WO2023108126A9 (en) 2023-08-24
CA3235948A1 (en) 2023-06-15
MX2024007105A (es) 2024-06-24
EP4444352A4 (en) 2025-12-17
KR20240141165A (ko) 2024-09-25
WO2023108126A1 (en) 2023-06-15
AU2022405604A2 (en) 2024-07-11
JP2024545981A (ja) 2024-12-17
ZA202404443B (en) 2025-10-29
US20250388638A1 (en) 2025-12-25
AU2022405604A1 (en) 2024-06-13
CN118613284A (zh) 2024-09-06
EP4444352A1 (en) 2024-10-16

Similar Documents

Publication Publication Date Title
US9074015B2 (en) Recombinantly expressed insulin polypeptides and uses thereof
CN101389650B (zh) 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
JP5749155B2 (ja) プロテアーゼ安定化アシル化インスリンアナログ
US20100261637A1 (en) Peptides derivatized with a-b-c-d- and their therapeutical use
EP3808369B1 (en) Use of il-22 dimers in manufacture of a medicament for intravenous administration
JP2003160598A (ja) 接合安定化されたポリペプチド組成物
CN105121459A (zh) 通过连接至促性腺激素羧基端肽来增加多肽的流体动力学体积的方法
EP4013395A1 (en) Compositions and particles for payload delivery
Lee et al. Genetic engineering of novel super long-acting Exendin-4 chimeric protein for effective treatment of metabolic and cognitive complications of obesity
US20250099599A1 (en) Furin-cleavable delivery constructs
EP3442562B1 (en) An il-22 dimer for use in treating necrotizing enterocolitis
WO2021037187A1 (zh) 一种多肽及其应用
US20250388638A1 (en) Compositions and methods for oral delivery
CN105142660A (zh) N末端截短的胰岛素类似物
AU2005265266A1 (en) Aequorin-containing compositions and methods of using same
HK40109249A (zh) 用於口服给予的组合物和方法
TW202535451A (zh) 經修飾之調酸素及其使用方法
WO2025117857A2 (en) Adp-ribosylation factor compositions and methods of use thereof
KR20170069997A (ko) 미리스토일화된 렙틴-관련된 펩티드 및 이들의 용도
HK40070502B (zh) 胰岛素衍生物
NZ622174A (en) Glucagon-like peptide-2 compositions and methods of making and using same
JPWO2023108126A5 (https=)
HK40002973A (en) An il-22 dimer for use in treating necrotizing enterocolitis
NZ622174B2 (en) Glucagon-like peptide-2 compositions and methods of making and using same